Single‐stage retrograde endoscopic common bile duct stone removal might be sufficient in moderate acute cholangitis with a stone size ≤12 mm: A retrospective cohort study with propensity score matching

Abstract

AbstractStudies elucidating the efficacy and safety of single‐stage endoscopic treatment for acute moderate cholangitis with choledocholithiasis are limited. Therefore, we performed a retrospective analysis of single‐stage endoscopic treatment for common bile duct (CBD) stone removal in patients with moderate cholangitis to determine the rates of successful stone extraction and complications. A retrospective chart review was conducted for all consecutive patients (n = 632) undergoing endoscopic retrograde cholangiopancreatography (ERCP) for CBD stone removal between January 2010 and September 2013 at the study institution. A total of 346 patients excluded based on the following criteria: procedural failure requiring an anatomy‐modifying operation, stenosis of the pyloric ring, tumor‐related obstruction, treatment requiring only biliary drainage, failure to locate the papilla, intolerance due to inadequate sedation, CBD stone > 12 mm, CBD sludge, and non‐naïve papilla in ERCP. The remaining 286 patients were randomly matched at a 1:2 ratio using propensity score together with age and sex with the Number Cruncher Statistical System statistical software. After propensity score matching, there were 90 and 134 patients in the moderate and no/mild cholangitis groups, respectively. The baseline characteristics and endoscopic findings were comparable between the two groups. The success rate of complete stone extraction was similar between the moderate and no/mild cholangitis groups (90.0% vs 91.0%, P = .793). Additionally, the complication rates were comparable between the moderate and no/mild cholangitis groups (post‐ERCP pancreatitis, 13.3% vs 10.4%, P = .542; pneumonia, 4.4% vs 1.5%, P = .183; perforation, 0% vs 1.5%, P = .243; and mortality, 2.2% vs 0.7%, P = .350). However, there was a trend for higher bleeding rate in the moderate cholangitis group compared with the no/mild cholangitis group (2.2% vs 0%, P = .084). Single‐stage retrograde endoscopic CBD stone removal in patients with moderate cholangitis and choledocholithiasis sized ≤12 mm might be adequate based on the high success rate (90.0%) for stone removal and low complication rates.